Harrow Health Inc

Compare

507 Followers

HROW Stock Chart & Stats

$36.78

-$0.36(-1.00%)

At close: Jan 08 4:00 PM EST

$36.78

-$0.36(-1.00%)

Day’s Range― - ―

52-Week Range$20.85 - $54.19

Previous CloseN/A

Volume51.77K

Average Volume (3M)825.13K

Market Cap

$1.41B

Enterprise Value$1.36B

Total Cash (Recent Filing)$52.96M

Total Debt (Recent Filing)$231.25M

Price to Earnings (P/E)―

Beta1.96

Next Earnings

Nov 10, 2025

EPS Estimate

0.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.13

Shares Outstanding37,002,136

10 Day Avg. Volume534,218

30 Day Avg. Volume825,129

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.97

Enterprise Value/Revenue5.99

Enterprise Value/Gross Profit8.04

Enterprise Value/Ebitda42.50

Forecast

1Y Price Target

$67.75

Price Target Upside84.20% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Product OfferingHarrow Access for All program aims to make it easier and more affordable for patients to access Harrow’s full range of branded, generic, and compounded ophthalmic medications.

Revenue GrowthSignificant revenue growth expected in the coming years.

Strategic PositioningThe goal of Harrow is to become the next great ophthalmic company and offer management solutions for the North America market.

Bears Say

Business VolatilityThe seasonality in the company’s underlying business could drive some volatility in the stock.

Debt ExpensesThe refinancing deal will likely bring forward some debt extinguishment expenses into the third quarter, potentially affecting estimates.

Harrow Health News

Harrow appoints Fank Mullery as CEO, ImprimisRx

Harrow (HROW) announced leadership changes at its wholly-owned subsidiary, ImprimisRx. Frank Mullery has been appointed as CEO and...

24d ago

HROW

Harrow price target raised to $74 from $70 at B. Riley

B. Riley raised the firm’s price target on Harrow (HROW) to $74 from $70 and keeps a Buy...

29d ago

HROW

Harrow Health Announces New Leadership at ImprimisRx

Harrow Health ( ($HROW) ) has issued an update. On October 6, 2025, Harrow, Inc. announced leadership changes...

24d ago

HROW

Harrow price target raised to $70 from $42 at Lake Street

Lake Street analyst Thomas Flaten raised the firm’s price target on Harrow (HROW) to $70 from $42 and...

1M ago

HROW

Harrow Health Secures New $40 Million Credit Facility

Harrow Health ( ($HROW) ) just unveiled an update. On September 26, 2025, Harrow, Inc. entered into a...

1M ago

HROW

Harrow Health’s Promising Growth Trajectory: Buy Rating Supported by Strategic Initiatives and Product Expansion

Harrow Health, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from...

1M ago

HROW

Harrow Health’s Promising Growth Trajectory: Analyst Recommends ‘Buy’ Amid Strategic Revenue Projections and Product Enthusiasm

Analyst Thomas Shrader of BTIG maintained a Buy rating on Harrow Health, retaining the price target of $63.00....

1M ago

HROW

Harrow Health Hosts Investor Day Presentation

Harrow Health ( ($HROW) ) has issued an update. On September 26, 2025, Harrow, Inc. hosted its Investor...

1M ago

HROW

Harrow targets $250M+ in quarterly revenue by 4Q27

Sees “confident” in this target, with revenue anticipated to be driven by the products’ best-in-class attributes, continued new...

1M ago

HROW

Morning Movers: Pharma, truck stocks react to Trump tariff announcements

Stock futures are inching higher after the latest inflation data, though sentiment is also being clouded by fresh...

1M ago

LLY

Harrow Health Acquires Melt Pharmaceuticals for Expansion

Harrow Health ( ($HROW) ) has issued an update. On September 26, 2025, Harrow announced its agreement to...

1M ago

HROW

Harrow enters agreement to acquire Melt Pharmaceuticals

Harrow (HROW) announced that it has entered into an agreement to acquire Melt Pharmaceuticals. The closing of this...

1M ago

HROW

Harrow to hold analyst and investor day

Analyst and Investor Day to be held on September 26 at 11:30 am. Webcast Link Published first on...

1M ago

HROW

Harrow Health’s Strategic Debt Restructuring and Acquisition Propel Buy Rating

Thomas Shrader, an analyst from BTIG, maintained the Buy rating on Harrow Health. The associated price target remains...

1M ago

HROW

HROW FAQ

What was Harrow Health Inc’s price range in the past 12 months?

Harrow Health Inc lowest stock price was $20.85 and its highest was $54.19 in the past 12 months.

What is Harrow Health Inc’s market cap?

Harrow Health Inc’s market cap is $1.41B.

When is Harrow Health Inc’s upcoming earnings report date?

Harrow Health Inc’s upcoming earnings report date is Nov 10, 2025 which is in 11 days.

How were Harrow Health Inc’s earnings last quarter?

Harrow Health Inc released its earnings results on Aug 11, 2025. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.008 by $0.122.

Is Harrow Health Inc overvalued?

According to Wall Street analysts Harrow Health Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Harrow Health Inc pay dividends?

Harrow Health Inc does not currently pay dividends.

What is Harrow Health Inc’s EPS estimate?

Harrow Health Inc’s EPS estimate is 0.22.

How many shares outstanding does Harrow Health Inc have?

Harrow Health Inc has 37,002,136 shares outstanding.

What happened to Harrow Health Inc’s price movement after its last earnings report?

Harrow Health Inc reported an EPS of $0.13 in its last earnings report, beating expectations of $0.008. Following the earnings report the stock price went up 3.231%.

Which hedge fund is a major shareholder of Harrow Health Inc?

Currently, no hedge funds are holding shares in HROW

Harrow Health Stock Smart Score

Outperform

Fundamentals

Return on Equity

-18.99%

Trailing 12-Months

Asset Growth

12.69%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Harrow Health Inc

Harrow Health (HROW) is a healthcare company focused on providing innovative pharmaceutical solutions, primarily in the areas of ophthalmology and other specialty therapeutic segments. The company develops, manufactures, and distributes a range of compounded sterile preparations, including eye care medications and other customized pharmaceutical products, tailored to meet specific patient needs. Harrow Health aims to improve patient outcomes through its proprietary formulations and strategic partnerships within the healthcare sector.

Harrow Health (HROW) Earnings & Revenues

Historic Earnings Reports

HROW Company Deck

HROW Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call conveyed strong growth and strategic developments with significant revenue increases and strategic alliances. However, there were challenges with the VEVYE revenue decline and underperformance in the specialty branded portfolio.View all HROW earnings summaries

HROW Stock 12 Month Forecast

Average Price Target

$67.75

▲(84.20% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"23":"$23","36":"$36","49":"$49","62":"$62","75":"$75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":74,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$74.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$67.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$63.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[23,36,49,62,75],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.37,50.34153846153846,52.31307692307692,54.284615384615385,56.25615384615384,58.22769230769231,60.199230769230766,62.17076923076923,64.1423076923077,66.11384615384615,68.08538461538461,70.05692307692308,72.02846153846154,{"y":74,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.37,49.86076923076923,51.35153846153846,52.84230769230769,54.33307692307692,55.823846153846155,57.31461538461538,58.80538461538461,60.29615384615384,61.786923076923074,63.277692307692305,64.76846153846154,66.25923076923077,{"y":67.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.37,49.495384615384616,50.62076923076923,51.746153846153845,52.871538461538464,53.996923076923075,55.12230769230769,56.247692307692304,57.37307692307692,58.49846153846154,59.62384615384615,60.74923076923077,61.87461538461538,{"y":63,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":44.45,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.64,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.86,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.55,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.72,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.98,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.98,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.77,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.23,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.72,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.37,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >